Advertisement

Treatment Resistance in Anxiety Disorder: Generalized Anxiety Disorder and Social Anxiety Disorder

  • Kang Soo Lee
  • Sang Hyuk Lee
Chapter

Abstract

Evidence-based treatments are suggested for generalized anxiety disorder (GAD) and social anxiety disorder (SAD). Pharmacological treatments such as selective serotonin reuptake inhibitors (SSRIs) and psychological treatment including cognitive-behavioral treatment (CBT) have been used as first-line treatments. However, many patients do not improve despite successful delivery of standard therapeutic interventions. The definition of treatment resistance is that standard treatments have been effectively delivered, but the results are ineffective. Overcoming treatment resistance requires reevaluation of the diagnosis and optimization of the treatments. Options for treatment-resistant GAD and SAD include augmentation with other antidepressants, atypical antipsychotics, benzodiazepines, and pregabalin. A partial NMDA agonist D-cycloserine was studied as a newer treatment option with exposure therapy in anxiety disorders.

Keywords

Generalized anxiety disorder Social anxiety disorder Treatment resistance SSRI SNRI Atypical antipsychotics CBT 

References

  1. 1.
    Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602.PubMedGoogle Scholar
  2. 2.
    Ballenger JC. Treatment of anxiety disorders to remission. J Clin Psychiatry. 2001;62:5–9.PubMedGoogle Scholar
  3. 3.
    Barlow DH, Lehman CL. Advances in the psychosocial treatment of anxiety disorders. Implications for national health care. Arch Gen Psychiatry. 1996;53(8):727–35.CrossRefGoogle Scholar
  4. 4.
    Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Bobes J, Beidel DC, et al. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 1998;59:54–60.PubMedGoogle Scholar
  5. 5.
    Ballenger JC, Davidson JR, Lecrubier Y, Nut DJ, Borkovec TD, Rickels K, et al. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 2001;62:53–8.PubMedGoogle Scholar
  6. 6.
    Ballenger JC. Current treatment of the anxiety disorders in adults. Biol Psychiatry. 1999;46(11):1579–94.CrossRefGoogle Scholar
  7. 7.
    Roy-Byrne P. Treatment-refractory anxiety; definition, risk factors, and treatment challenges. Dialogues Clin Neurosci. 2015;17(2):191–206.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Brown C, Schulberg HC, Madonia MJ, Shear MK, Houck PR. Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders. Am J Psychiatry. 1996;153(10):1293–300.CrossRefGoogle Scholar
  9. 9.
    Bystritsky A. Treatment-resistant anxiety disorders. Mol Psychiatry. 2006;11(9):805–14.CrossRefGoogle Scholar
  10. 10.
    Pollack MH, Otto MW, Roy-Byrne PP, Coplan JD, Rothbaum BO, Simon NM, et al. Novel treatment approaches for refractory anxiety disorders. Depress Anxiety. 2008;25(6):467–76.CrossRefGoogle Scholar
  11. 11.
    Klumpp H, Keutmann MK, Fitzgerald DA, Shankman SA, Phan KL. Resting state amygdala-prefrontal connectivity predicts symptom change after cognitive behavioral therapy in generalized social anxiety disorder. Biol Mood Anxiety Disord. 2014;4(1):14.CrossRefGoogle Scholar
  12. 12.
    Roy-Whitfield-Gabrieli S, Ghosh SS, Nieto-Castanon A, Saygin Z, Doehrmann O, Chai XJ, et al. Brain connectomics predict response to treatment in social anxiety disorder. Mol Psychiatry. 2016;21(5):680–5.CrossRefGoogle Scholar
  13. 13.
    Byrne P, Cowley DS. Clinical approach to treatment-resistant panic disorder. In: Rosenbaum JF, Pollack MH, editors. Panic disorder and its treatment. New York: Marcel Dekker; 1998. p. 205–27.Google Scholar
  14. 14.
    Blanco C, Raza MS, Schneier FR, Liebowitz MR. The evidence-based pharmacological treatment of social anxiety disorder. Int J Neuropsychopharmacol. 2003;6(4):427–42.CrossRefGoogle Scholar
  15. 15.
    Lauria-Horner BA, Pohl RB. Pregabalin: a new anxiolytic. Expert Opin Investig Drugs. 2003;12(4):663–72.CrossRefGoogle Scholar
  16. 16.
    McDougle CJ, Barr LC, Goodman WK, Price LH. Possible role of neuropeptides in obsessive compulsive disorder. Psychoneuroendocrinology. 1999;24(1):1–24.CrossRefGoogle Scholar
  17. 17.
    Nemeroff CB. New vistas in neuropeptide research in neuropsychiatry: focus on corticotrophin releasing factor. Neuropsychopharmacology. 1992;6:69–75.PubMedGoogle Scholar
  18. 18.
    Herranz R. Cholecystokinin antagonists: pharmacological and therapeutic potential. Med Res Rev. 2003;23(5):559–605.CrossRefGoogle Scholar
  19. 19.
    Holmes A, Heilig M, Rupniak NMJ, Steckler T, Griebel G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci. 2003;24(11):580–8.CrossRefGoogle Scholar
  20. 20.
    Adams JB, Pyke RE, Costa J, Cutler NR, Schweizer E, Wilcox CS, et al. A double blind, placebo controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. J Clin Psychopharmacol. 1995;15(6):428–34.CrossRefGoogle Scholar
  21. 21.
    Borkovec TD, Ruscio AM. Psychotherapy for generalized anxiety disorder. J Clin Psychiatry. 2001;62:37–42.PubMedGoogle Scholar
  22. 22.
    Krisanaprakornkit T, Sriraj W, Piyavhatkul N, Laopaiboon M. Meditation therapy for anxiety disorders. Cochrane Database Syst Rev. 2006;1:CD004998.Google Scholar
  23. 23.
    Hambrick JP, Weeks JW, Harb GC, Heimberg RG. Cognitive behavioral therapy for social anxiety disorder: supporting evidence and future directions. CNS Spectr. 2003;8(5):373–81.CrossRefGoogle Scholar
  24. 24.
    Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry. 2004;61(11):1136–44.CrossRefGoogle Scholar
  25. 25.
    Walker DL, Ressler KJ, Lu KT, Davis M. Facilitation of conditioned fear extinction by systemic administration of intraamygdala infusions of D-cycloserine as assessed with fear potentiated startle in rats. J Neurosci. 2002;22(6):2343–51.CrossRefGoogle Scholar
  26. 26.
    Hofmann SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K, et al. Augmentation of exposure therapy for social anxiety disorder with D-Cycloserine. Arch Gen Psychiatry. 2006;63(3):298–304.CrossRefGoogle Scholar
  27. 27.
    Canadian Psychiatric Association. Clinical practice guidelines: management of anxiety disorders. Can J Psychiatr. 2006;51(8 Suppl 2):9S.Google Scholar
  28. 28.
    Rubio G, Lopez-Ibor JJ. Generalized anxiety disorder: a 40-year follow-up study. Acta Psychiatr Scand. 2007;115(5):372–9.CrossRefGoogle Scholar
  29. 29.
    Yonkers KA, Warshaw MG, Massion AO, Keller MB. Phenomenology and course of generalized anxiety disorder. Br J Psychiatry. 1996;168(3):308–13.CrossRefGoogle Scholar
  30. 30.
    Pollack MH. Refractory generalized anxiety disorder. J Clin Psychiatry. 2009;70(Suppl 2):32–8.CrossRefGoogle Scholar
  31. 31.
    National Institute for Health and Clinical Excellence. Clinical guideline 22 (Amended). Anxiety: management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. Available from at: http://www.nice.org.uk/CG022NICEguideline.
  32. 32.
    Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005;19(6):567–96.CrossRefGoogle Scholar
  33. 33.
    Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry. 2008;9(4):248–312.CrossRefGoogle Scholar
  34. 34.
    Ipser JC, Carey P, Dhansay Y, Fakier N, Seedat S, Stein DJ. Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database Syst Rev. 2006;4:CD005473.Google Scholar
  35. 35.
    Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2005;66(10):1321–5.CrossRefGoogle Scholar
  36. 36.
    Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006;59:211–5.CrossRefGoogle Scholar
  37. 37.
    Simon NM, Hoge EA, Fischmann D, Worthington JJ, Christian KM, Kinrys G, et al. An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry. 2006;67(3):381–5.CrossRefGoogle Scholar
  38. 38.
    Patterson B, Van Ameringen M. Augmentation strategies for treatment-resistant anxiety disorders: a systematic review and meta-analysis. Depress Anxiety. 2016;33(8):728–36.CrossRefGoogle Scholar
  39. 39.
    Adson DE, Kushner MG, Fahnhorst TA. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J Affect Disord. 2005;86(1):99–104.CrossRefGoogle Scholar
  40. 40.
    Worthington JJ III, Kinrys G, Wygant LE, Pollack MH. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol. 2005;20(1):9–11.CrossRefGoogle Scholar
  41. 41.
    Menza MA, Dobkin RD, Marin H. An open label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder. J Clin Psychopharmacol. 2007;27(2):207–10.CrossRefGoogle Scholar
  42. 42.
    Hoge EA, Worthington IIIJJ, Kaufman RE, Delong HR, Pollack MH, Simon NM. Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr. 2008;13(6):522–7.CrossRefGoogle Scholar
  43. 43.
    Snyderman SH, Rynn MA, Rickels K. Open-label pilot study of ziprasidone for refractory generalized anxiety disorder. J Clin Psychopharmacol. 2005;25(5):497–9.CrossRefGoogle Scholar
  44. 44.
    Schwartz TL. The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series. Psychopharmacol Bull. 2002;36(2):53–7.PubMedGoogle Scholar
  45. 45.
    Pollack MH, Matthews J, Scott EL. Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry. 1998;155(7):992–3.CrossRefGoogle Scholar
  46. 46.
    Pollack M. Levetiracetam (Keppra) for anxiety. Curbside Consult. 2002;1(4):4.Google Scholar
  47. 47.
    Crane D. Tiagabine for the treatment of anxiety. Depress Anxiety. 2003;18(1):51–2.CrossRefGoogle Scholar
  48. 48.
    Feltner DE, Pollack MH, Davidson JR, Stein MB, Fulterer R, Jefferson JW, et al. A placebo-controlled, double-blind study of pregabalin treatment of social phobia: outcome and predictors of response. J Eur Coll Neuropsychopharmacol. 2000;10:344–5.CrossRefGoogle Scholar
  49. 49.
    Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005;62(9):1022–30.CrossRefGoogle Scholar
  50. 50.
    Montgomery S, Chatamra K, Pauer L, Whalen E, Baldinetti F. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry. 2008;193(5):389–94.CrossRefGoogle Scholar
  51. 51.
    Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, et al. A randomized, double-blind, placebo controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2003;23(3):240–9.PubMedGoogle Scholar
  52. 52.
    Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry. 2003;160(3):533–40.CrossRefGoogle Scholar
  53. 53.
    Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry. 2006;67(5):771–82.CrossRefGoogle Scholar
  54. 54.
    Stein MB, Stein DJ. Social anxiety disorder. Lancet. 2008;371(9618):1115–25.CrossRefGoogle Scholar
  55. 55.
    Bandelow B, Baldwin DS, Dolberg OT, Andersen HF, Stein DJ. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder. J Clin Psychiatry. 2006;67(9):1428–34.CrossRefGoogle Scholar
  56. 56.
    Stein DJ, Stein MB, Pitts CD, Kumar R, Hunter B. Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. J Clin Psychiatry. 2002;63:152–5.CrossRefGoogle Scholar
  57. 57.
    Pallanti S, Quercioli L. Resistant social anxiety disorder response to escitalopram. Clin Pract Epidemiol Ment Health. 2006;2(1):35.CrossRefGoogle Scholar
  58. 58.
    Kelsey JE. Venlafaxine in social phobia. Psychopharmacol Bull. 1995;31:767–71.PubMedGoogle Scholar
  59. 59.
    Altamura AC, Pioli R, Vitto M, Mannu P. Venlafaxine in social phobia: a study in selective serotonin reuptake non-responders. Int Clin Psychopharmacol. 1999;14(4):239–45.CrossRefGoogle Scholar
  60. 60.
    Aarre TF. Phenelzine efficacy in refractory social anxiety disorder: a case series. Nord J Psychiatry. 2003;57(4):313–5.CrossRefGoogle Scholar
  61. 61.
    Simon NM, Korbly NB, Worthington JJ, Kinrys G, Pollack MH. Citalopram for social anxiety disorder: an open-label pilot study in refractory and nonrefractory patients. CNS Spectr. 2002;7(9):655–7.CrossRefGoogle Scholar
  62. 62.
    Altamura AC, Pioli R, Vitto M, Mannu P. Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders. Int Clin Psychopharmacol. 1999;14(4):239–45.CrossRefGoogle Scholar
  63. 63.
    Barnett SD, Kramer ML, Casat CD, Connor KM, Davidson JR. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol. 2002;16(4):365–8.CrossRefGoogle Scholar
  64. 64.
    Shaywitz JE, Liebowitz MR. Antiepileptic treatment of anxiety disorders. Prim Psychiatry. 2003:51–6.Google Scholar
  65. 65.
    Van Ameringen M, Mancini C, Pipe B, Oakman J, Bennett M. An open-label trial of topiramate in the treatment of generalized social phobia. J Clin Psychiatry. 2004;65(12):1674–8.CrossRefGoogle Scholar
  66. 66.
    Kinrys G, Pollack MH, Simon NM, Worthington JJ, Nardi AE, Versiani M. Valproic acid for the treatment of social anxiety disorder. Int Clin Psychopharmacol. 2003;18(3):169–72.PubMedGoogle Scholar
  67. 67.
    Simon NM, Worthington JJ, Doyle AC, Hoge EA, Kinrys G, Fischmann D, et al. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry. 2004;65(9):1219–22.CrossRefGoogle Scholar
  68. 68.
    Van Ameringen M, Mancini C, Wilson C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord. 1996;39(2):115–21.CrossRefGoogle Scholar
  69. 69.
    Stein MB, Sareen J, Hami S, Chao J. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry. 2001;158(10):1725–7.CrossRefGoogle Scholar
  70. 70.
    Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry. 2004;65(2):244–8.PubMedGoogle Scholar
  71. 71.
    Blanco C, Heimberg RG, Schneier FR, Fresco DM, Chen H, Turk CL, et al. A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry. 2010;67(3):286–95.CrossRefGoogle Scholar
  72. 72.
    Blanco C, Okuda M, Markowitz JC, Liu SM, Grant BF, Hasin DS. The epidemiology of chronic major depressive disorder and dysthymic disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2010;71(12):1645–56.CrossRefGoogle Scholar
  73. 73.
    Guastella AJ, Richardson R, Lovibond PF, et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry. 2008;63:544–9.CrossRefGoogle Scholar
  74. 74.
    Mayo WE, Dias S, Mavranezouli I, Kew K, Clark DM, Ades AE, et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta analysis. Lancet Psychiatry. 2014;1(5):368–76.CrossRefGoogle Scholar
  75. 75.
    Craske MG, Golinelli D, Stein MB, Roy-Byrne P, Bystritsky A, Sherbourne C. Does the addition of cognitive behavioral therapy improve panic disorder treatment outcome relative to medication alone in the primary care setting? Psychol Med. 2005;35(11):1645–54.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Kang Soo Lee
    • 1
  • Sang Hyuk Lee
    • 1
  1. 1.Department of Psychiatry, School of MedicineCHA University, CHA Bundang Medical CenterSeongnamSouth Korea

Personalised recommendations